cckb receptor

CCK-B Receptor Antagonist 1 is a cholecystokinin B (CCK-B) receptor agonist and has the potential of reducing the secretion of gastric acid.

Pentagastrin (ICI-50123) is a synthetic polypeptide that mimics the effects of gastrin when administered parenterally, influencing the secretion and synthesis of salivary proteins.

Itriglumide (CR-2945) is a cholecystokinin (CCK)-2 receptor antagonist with antisecretory and antiulcerogenic properties.

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin/CCK-B (IC50: 0.43 nM). It also inhibits gastrin/CCK-A activity (IC50: 1.82 μM).

CCKBR agonist-2 (Compound z-44) is a CCKBR-Gi-biased agonist that activates the Gi signaling pathway (EC50 = 0.27 nM) with negligible activity on Gq and Gs pathways. It exhibits no significant protective effect in mouse models of Alzheimer's disease.

Selective CCK2 receptor antagonist

PD 135158 is a CCK2 receptor antagonist.

PD-149164 is an agonist of the CCK-A receptor.

TP-680 is a antagonist of cholecystokininA receptor.

RP-72540 is a cholecystokinin B receptor antagonist. RP 72540 showed selectivity factors in express of 200 for CCKA versus CCKB receptors and also had high affinity for gastrin binding sites in the stomach. Administration of RP-72540 resulted in a dose-de